Project Grant K99DA062786
- Federal Grant Award Summary The National Institute on Drug Abuse awarded a Project Grant totaling $144,252 to the University of Massachusetts Medical School (UMMS) under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2025, with a completion date of August 31, 2030. This mentoring-focused award supports Dr. Carreiro's research program in precision medicine and digital biomarkers for opioid use disorder (OUD) prevention and treatment. The grant funds three integrated...
- Federal Project Grant Award Summary Baystate Medical Center, Inc. received a $187,023 Project Grant award from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning September 1, 2025, with a completion date of August 31, 2030. This mentored research career development award funds a mixed-methods study evaluating Massachusetts's Behavioral Health Supports for Justice-Involved Individuals (BH-JI) program, a statewide Medicaid initiative...
- Federal Grant Award Summary Yale University received a $2.33 million Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective May 1, 2025 through February 28, 2030. This research initiative focuses on imaging brain kappa opioid receptors (KOR) in individuals with opioid use disorder (OUD) during early abstinence using positron emission tomography (PET) imaging with the [11C]EKAP tracer. The study will compare KOR...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a Mentored Research Scientist Development Award (K01) totaling $399,600 under the Drug Use and Addiction Research Programs (CFDA 93.279) to support a five-year career development and mentored research initiative. Awarded on August 15, 2025, with completion targeted for July 31, 2030, this grant funds Dr. Jason Brian Gibbons at the University of Colorado Anschutz Medical Campus to develop machine learning-based...
- Federal Grant Award Summary The National Institute on Drug Abuse awarded a $159,615 Project Grant to Icahn School of Medicine at Mount Sinai on July 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research titled "Predicting Craving and Relapse Using Neurobehavioral Markers of Goals and Habits in Opioid Use Disorder," which addresses the critical public health challenge of opioid overdose deaths exceeding 100,000 annually in 2022. The...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a $194,903 Project Grant to the University of Pennsylvania on April 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) funding mechanism. This five-year research project, extending through March 31, 2030, supports Dr. Ashish Thakrar's research on methadone loading dose initiation for hospitalized patients with opioid use disorder (OUD) related to fentanyl use. The project addresses a...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of South Carolina a Project Grant of $192,149 under the Drug Use and Addiction Research Programs (CFDA 93.279) for the period February 1, 2026, through January 31, 2028. This research project investigates the noradrenergic mechanisms underlying stress-induced opioid reinstatement, specifically examining how stress exposure triggers increased cytokine release and heightened activity in the locus...
- Federal Project Grant Award Summary Yale University received a $195,048 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) for the period September 1, 2025, through August 31, 2030. This award supports the development of a culturally adapted contingency management (CM) intervention designed to address stimulant use disorder in the New Haven, Connecticut community. Contingency management is a behavioral economics-based...
- Federal Project Grant Award Summary Massachusetts General Hospital received a $742,500 Project Grant (R34) awarded on July 15, 2025, by the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279). The three-year pilot award funds the development and testing of an innovative tobacco cessation intervention delivered by Peer Recovery Coaches (PRCs) in recovery from both opioid use disorder (OUD) and tobacco use disorder (TUD). The primary deliverables...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Massachusetts Medical School a Project Grant totaling $1,171,950 under the Drug Use and Addiction Research Programs (CFDA 93.279) on July 15, 2025, with a completion date of March 31, 2030. This research grant funds the discovery and functional characterization of long non-coding RNAs (lncRNAs) in opioid use disorder (OUD) within the context of HIV at single-cell resolution. The project addresses...
The University of Connecticut Health Center received a $191,700 K99/R00 Project Grant award from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) on February 15, 2026. The grant supports research to identify and validate mechanisms of action (MOA) underlying peer recovery support (PRS) services for individuals with opioid use disorder (OUD). During the K99 phase, the research team will develop a client-centered assessment battery measuring MOA of PRS through collaboration with community boards of individuals with lived experience of OUD and certified peer recovery specialists. This phase includes qualitative research activities using human-centered design principles and iterative refinement of assessment tools. The deliverables include identification of potential MOA, compilation of appropriate assessment instruments, and refinement of those assessments through qualitative interviews and think-aloud protocols involving approximately 20 participants. During the R00 phase, the research team will integrate the refined assessment battery into an ongoing clinical trial (N=82) to examine effects of a PRS program on identified MOA, then develop an MOA-enhanced PRS program co-designed with community boards. The R00 phase will evaluate the feasibility and acceptability of the enhanced program, with completion targeted for January 31, 2028. This research addresses the ongoing public health crisis of opioid-related overdose deaths by developing evidence-based strategies to improve treatment retention through peer support mechanisms, ultimately contributing to more effective OUD treatment outcomes.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $191.7k | 2/3/26 |